Ocean Thermal Energy Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Ocean Thermal Energy Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.01M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 24, 2026 |
| FY2019 | Dec 31, 2018 | $0 | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $3.9K | Apr 4, 2017 |
| FY2015 | Dec 31, 2014 | $8.3K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $122.3K | Aug 31, 2015 |
| FY2013 | Dec 31, 2012 | $252.4K | Aug 31, 2015 |
| FY2012 | Dec 31, 2011 | $569.8K | Aug 31, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $588.9K | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 24, 2026 |
| FY2016 | Dec 31, 2016 | $49 | Apr 4, 2017 |
| FY2016 | Dec 31, 2015 | $3.8K | Apr 4, 2017 |
| FY2015 | Dec 31, 2014 | $5.2K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $78.9K | Aug 31, 2015 |
| FY2013 | Dec 31, 2012 | $217.5K | Aug 31, 2015 |
| FY2012 | Dec 31, 2011 | $217.1K | Aug 31, 2015 |
| FY2011 | Dec 31, 2010 | $315.0K | Mar 29, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($69.30M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($1.19M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($9.26M) | Oct 27, 2025 |
| FY2024 | Dec 31, 2022 | ($6.91M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($2.67M) | Sep 5, 2023 |
| FY2021 | Dec 31, 2020 | ($6.45M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($4.88M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($7.88M) | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | ($14.59M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($6.11M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($172.1K) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($1.58M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($1.50M) | Oct 27, 2025 |
| FY2024 | Dec 31, 2022 | ($1.52M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($1.98M) | Sep 5, 2023 |
| FY2021 | Dec 31, 2020 | ($2.78M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($1.80M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($4.05M) | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | ($12.70M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($3.43M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $0 | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | $341 | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $60.9K | Aug 31, 2015 |
| FY2013 | Dec 31, 2012 | $108.4K | Aug 31, 2015 |
| FY2012 | Dec 31, 2011 | $159.2K | Aug 31, 2015 |
| FY2011 | Dec 31, 2010 | $162.2K | Mar 29, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($93.4K) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($562.6K) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($669.5K) | Oct 27, 2025 |
| FY2024 | Dec 31, 2022 | ($327.2K) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($542.6K) | Sep 5, 2023 |
| FY2021 | Dec 31, 2020 | ($827.1K) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($616.8K) | Mar 30, 2021 |
| FY2015 | Dec 31, 2015 | ($183.0K) | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | ($86.3K) | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | ($750) | Aug 31, 2015 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $0 | Mar 29, 2012 |
| FY2011 | Dec 31, 2010 | $0 | Mar 29, 2012 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.48M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $21.1K | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $120.1K | Oct 27, 2025 |
| FY2024 | Dec 31, 2022 | $6.4K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $6.0K | Sep 5, 2023 |
| FY2021 | Dec 31, 2020 | $17.4K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $43.2K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $9.1K | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $1.34M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $886.7K | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.89M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $44.57M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $44.05M | Oct 27, 2025 |
| FY2024 | Dec 31, 2022 | $36.21M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $30.03M | Sep 5, 2023 |
| FY2021 | Dec 31, 2020 | $28.43M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $22.11M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $17.78M | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $11.85M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $9.55M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($113.40M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($44.55M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2023 | ($43.93M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2022 | ($36.20M) | Oct 27, 2025 |
| FY2024 | Dec 31, 2021 | ($30.03M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | ($28.41M) | Sep 5, 2023 |
| FY2021 | Dec 31, 2019 | ($22.07M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | ($17.77M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | ($10.51M) | Mar 20, 2020 |
| FY2018 | Dec 31, 2016 | ($8.66M) | Mar 22, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($176.56M) | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($107.27M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | ($106.08M) | Oct 27, 2025 |
| FY2024 | Dec 31, 2022 | ($96.50M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($89.58M) | Sep 5, 2023 |
| FY2021 | Dec 31, 2020 | ($86.91M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($80.46M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($75.58M) | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | ($67.70M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($53.11M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $957 | Mar 30, 2022 |
| FY2021 | Dec 31, 2020 | $7.4K | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | $23.2K | Mar 30, 2022 |
| FY2015 | Dec 31, 2015 | $4.7K | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | $178 | Mar 30, 2016 |
| FY2015 | Dec 31, 2013 | $11.5K | Mar 30, 2016 |
| FY2014 | Dec 31, 2012 | $857 | Aug 31, 2015 |
| FY2013 | Dec 31, 2011 | $18.6K | Aug 31, 2015 |
| FY2012 | Dec 31, 2010 | $65.0K | Aug 31, 2015 |
| FY2011 | Dec 31, 2009 | $123.8K | Mar 29, 2012 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $369.4K | Mar 30, 2021 |
| FY2020 | Dec 31, 2019 | $182.5K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $168.3K | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $687.3K | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $602.1K | Apr 2, 2018 |
| FY2015 | Dec 31, 2015 | $299.6K | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | $299.6K | Mar 30, 2016 |
| FY2013 | Dec 31, 2013 | $299.6K | Aug 31, 2015 |
| FY2013 | Dec 31, 2012 | $300.3K | Aug 31, 2015 |
| FY2012 | Dec 31, 2011 | $309.3K | Aug 31, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 0 | Sep 5, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Sep 5, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 30, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Oct 27, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 190.01M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | 190.01M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | 184.37M | Oct 27, 2025 |
| FY2024 | Dec 31, 2022 | 184.37M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 174.37M | Sep 5, 2023 |
| FY2021 | Dec 31, 2020 | 137.85M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 134.78M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 131.04M | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | 122.64M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | 94.34M | Apr 2, 2018 |